FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022781679> ?p ?o ?g. }

• W2022781679 endingPage "191" @default.
• W2022781679 startingPage "181" @default.
• W2022781679 abstract "To evaluate the cost-effectiveness of recombinant human activated protein C (rhAPC) compared with usual therapy for patients with severe sepsis, and also to determine the influence that severity of illness exerts on cost-effectiveness.We use a Markov model-based cost-effectiveness analysis of treatment strategies for patients with severe sepsis. Therapy includes treatment with either rhAPC and usual therapy, or usual therapy alone. Probabilities for clinical outcomes were obtained from a large randomized clinical trial comparing the use of rhAPC with placebo (PROWESS study) and from outcomes literature for patients with severe sepsis and its complications. Cost estimates were based on Medicare reimbursement rates, Health Care Financing Administration information and the literature. Outcome measures include life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness.Compared with usual therapy alone, rhAPC treatment for patients with very severe sepsis (APACHE II score > or = 25) was associated with an incremental cost-effectiveness ratio of $13 493/QALY. Treatment of patients with less severe sepsis with rhAPC (APACHE II score < 25) had an incremental cost-effectiveness ratio of $403,000/QALY. For patients with very severe sepsis the incremental cost-effectiveness ratio for treatment with rhAPC remained under $30,000/QALY, over a broad range of variables, including costs of rhAPC, costs of acute care and costs and probabilities of complications of treatment. For patients with less severe sepsis, drug costs would need to fall well below current market price before achieving cost-effectiveness. A probabilistic sensitivity analysis comparing rhAPC treatment with usual therapy for patients with very severe sepsis showed that < 1% of Monte Carlo simulations had incremental cost-effectiveness ratios > $50,000/QALY.The use of rhAPC for the treatment of patients with very severe sepsis, as determined by APACHE II score > or = 25, appears cost-effective, while treatment of patients with APACHE II score < 25 is not cost-effective." @default.
• W2022781679 created "2016-06-24" @default.
• W2022781679 creator A5027035574 @default.
• W2022781679 creator A5034546097 @default.
• W2022781679 creator A5034827086 @default.
• W2022781679 creator A5035524531 @default.
• W2022781679 creator A5049163875 @default.
• W2022781679 creator A5064473600 @default.
• W2022781679 date "2003-09-01" @default.
• W2022781679 modified "2023-10-06" @default.
• W2022781679 title "Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis" @default.
• W2022781679 cites W132642117 @default.
• W2022781679 cites W1537598136 @default.
• W2022781679 cites W1965941534 @default.
• W2022781679 cites W1977032474 @default.
• W2022781679 cites W1980187445 @default.
• W2022781679 cites W1983567452 @default.
• W2022781679 cites W1997517387 @default.
• W2022781679 cites W1999789157 @default.
• W2022781679 cites W2002306982 @default.
• W2022781679 cites W2009975233 @default.
• W2022781679 cites W2026722066 @default.
• W2022781679 cites W2042729758 @default.
• W2022781679 cites W2043772350 @default.
• W2022781679 cites W2045012616 @default.
• W2022781679 cites W2049927822 @default.
• W2022781679 cites W2071595387 @default.
• W2022781679 cites W2075643315 @default.
• W2022781679 cites W2090489225 @default.
• W2022781679 cites W2094145886 @default.
• W2022781679 cites W2106632488 @default.
• W2022781679 cites W2112930056 @default.
• W2022781679 cites W2156618518 @default.
• W2022781679 cites W2160691650 @default.
• W2022781679 cites W2322121630 @default.
• W2022781679 cites W2341811425 @default.
• W2022781679 cites W2462988942 @default.
• W2022781679 cites W2768146862 @default.
• W2022781679 cites W4233619444 @default.
• W2022781679 cites W4237675714 @default.
• W2022781679 cites W4248254320 @default.
• W2022781679 cites W4249334197 @default.
• W2022781679 cites W4251028200 @default.
• W2022781679 cites W4254674135 @default.
• W2022781679 doi "https://doi.org/10.1016/j.jcrc.2003.08.009" @default.
• W2022781679 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14595571" @default.
• W2022781679 hasPublicationYear "2003" @default.
• W2022781679 type Work @default.
• W2022781679 sameAs 2022781679 @default.
• W2022781679 citedByCount "42" @default.
• W2022781679 countsByYear W20227816792012 @default.
• W2022781679 countsByYear W20227816792013 @default.
• W2022781679 countsByYear W20227816792014 @default.
• W2022781679 countsByYear W20227816792015 @default.
• W2022781679 countsByYear W20227816792016 @default.
• W2022781679 countsByYear W20227816792017 @default.
• W2022781679 countsByYear W20227816792019 @default.
• W2022781679 countsByYear W20227816792020 @default.
• W2022781679 countsByYear W20227816792021 @default.
• W2022781679 crossrefType "journal-article" @default.
• W2022781679 hasAuthorship W2022781679A5027035574 @default.
• W2022781679 hasAuthorship W2022781679A5034546097 @default.
• W2022781679 hasAuthorship W2022781679A5034827086 @default.
• W2022781679 hasAuthorship W2022781679A5035524531 @default.
• W2022781679 hasAuthorship W2022781679A5049163875 @default.
• W2022781679 hasAuthorship W2022781679A5064473600 @default.
• W2022781679 hasConcept C112930515 @default.
• W2022781679 hasConcept C126322002 @default.
• W2022781679 hasConcept C160735492 @default.
• W2022781679 hasConcept C162324750 @default.
• W2022781679 hasConcept C168563851 @default.
• W2022781679 hasConcept C177713679 @default.
• W2022781679 hasConcept C2778384902 @default.
• W2022781679 hasConcept C2779703844 @default.
• W2022781679 hasConcept C2779900020 @default.
• W2022781679 hasConcept C3019080777 @default.
• W2022781679 hasConcept C50522688 @default.
• W2022781679 hasConcept C515549039 @default.
• W2022781679 hasConcept C64332521 @default.
• W2022781679 hasConcept C71924100 @default.
• W2022781679 hasConceptScore W2022781679C112930515 @default.
• W2022781679 hasConceptScore W2022781679C126322002 @default.
• W2022781679 hasConceptScore W2022781679C160735492 @default.
• W2022781679 hasConceptScore W2022781679C162324750 @default.
• W2022781679 hasConceptScore W2022781679C168563851 @default.
• W2022781679 hasConceptScore W2022781679C177713679 @default.
• W2022781679 hasConceptScore W2022781679C2778384902 @default.
• W2022781679 hasConceptScore W2022781679C2779703844 @default.
• W2022781679 hasConceptScore W2022781679C2779900020 @default.
• W2022781679 hasConceptScore W2022781679C3019080777 @default.
• W2022781679 hasConceptScore W2022781679C50522688 @default.
• W2022781679 hasConceptScore W2022781679C515549039 @default.
• W2022781679 hasConceptScore W2022781679C64332521 @default.
• W2022781679 hasConceptScore W2022781679C71924100 @default.
• W2022781679 hasIssue "3" @default.
• W2022781679 hasLocation W20227816791 @default.
• W2022781679 hasLocation W20227816792 @default.
• W2022781679 hasOpenAccess W2022781679 @default.

• next